PartnershipMay 4, 2026, 04:11 PM
Helus Pharma Partners with TARA Mind for HLP003 Phase 3 Recruitment
AI Summary
Helus Pharma, operating as Cybin Inc., announced a partnership with TARA Mind to support clinical trial recruitment for its HLP003 Phase 3 program for Major Depressive Disorder. This collaboration aims to expand mental health awareness and access within the veteran community, directly aligning with President Trump's recent Executive Order on accelerating medical treatments for serious mental illness. TARA Mind will leverage its networks to facilitate veteran engagement for the FDA Breakthrough Therapy-designated HLP003 program.
Key Highlights
- Helus Pharma partnered with TARA Mind to advance veteran mental health initiatives.
- The collaboration supports recruitment for Helus Pharma's PARADIGM HLP003 Phase 3 program for Major Depressive Disorder (MDD).
- The partnership expands mental health awareness and access within the veteran community.
- It aligns with President Trump's April 18, 2026 Executive Order on accelerating mental health treatments.
- HLP003 has received FDA Breakthrough Therapy Designation.
- Helus Pharma is also developing HLP004 in Phase 2 for Generalized Anxiety Disorder.
Price Impact
More from HELP